| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
7,630 |
5,816 |
$564K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
12,138 |
7,198 |
$374K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
2,198 |
1,387 |
$372K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
896 |
271 |
$97K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,904 |
2,288 |
$46K |
| 87511 |
|
1,567 |
1,153 |
$36K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,565 |
1,153 |
$36K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,568 |
1,154 |
$36K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,566 |
1,153 |
$36K |
| 87563 |
|
1,588 |
1,162 |
$35K |
| 87640 |
|
1,483 |
1,157 |
$34K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,459 |
1,136 |
$33K |
| 87529 |
|
626 |
581 |
$26K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
466 |
442 |
$26K |
| 87653 |
|
1,111 |
987 |
$25K |
| 87634 |
|
468 |
442 |
$19K |
| 87481 |
|
218 |
205 |
$12K |
| 87541 |
|
466 |
442 |
$11K |
| 87581 |
|
466 |
442 |
$11K |
| 87486 |
|
466 |
442 |
$11K |
| 86738 |
|
574 |
398 |
$5K |
| 86780 |
|
573 |
398 |
$5K |
| 86413 |
|
109 |
104 |
$3K |
| 87498 |
|
110 |
105 |
$2K |
| 87532 |
|
109 |
104 |
$2K |
| 87496 |
|
109 |
104 |
$2K |
| 87556 |
|
109 |
104 |
$2K |
| 87503 |
|
109 |
104 |
$1K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
52 |
43 |
$1K |
| 87641 |
|
30 |
26 |
$598.50 |
| 87500 |
|
28 |
25 |
$574.56 |
| 87590 |
|
29 |
26 |
$342.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
13 |
13 |
$333.58 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
14 |
12 |
$247.38 |
| 84443 |
Thyroid stimulating hormone (TSH) |
13 |
12 |
$218.40 |
| 80053 |
Comprehensive metabolic panel |
13 |
12 |
$137.28 |
| 85027 |
|
13 |
12 |
$84.11 |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
1,309 |
608 |
$0.00 |
| 87631 |
|
109 |
104 |
$0.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
129 |
97 |
$0.00 |
| P9615 |
Catheterization for collection of specimen(s) (multiple patients) |
1,352 |
630 |
$0.00 |